Moneycontrol
Last Updated : Jun 14, 2018 10:42 AM IST | Source: Moneycontrol.com

Cipla gains 2% on USFDA approval for generic Isuprel

The company has received final approval for its abbreviated new drug application (ANDA) for Isoproterenol hydrochloride injection USP, 0.2mg/mL, single - use sterile Ampoule from the United States Food and Drug Administration (USFDA).

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Cipla gained 2 percent intraday Thursday as company received final USFDA approval for Isoproterenol hydrochloride injection.

The company has received final approval for its abbreviated new drug application (ANDA) for Isoproterenol hydrochloride injection USP, 0.2mg/mL, single - use sterile Ampoule from the United States Food and Drug Administration (USFDA).

Cipla’s Isoproterenol hydrochloride injection is AP - rated generic therapeutic equivalent version of Hospira Inc’s Isuprel injection and is indicated for the treatment of cardiac problems and heart block.

According to IQVIA (IMS Health) , Isuprel Injection and its generic equivalents had US sales of approximately $1 48 M for the 12 - month period ending April 2018.

At 10:22 hrs Cipla was quoting at Rs 585.95, up Rs 4.55, or 0.78 percent on the BSE.

Posted by Rakesh Patil
First Published on Jun 14, 2018 10:40 am
Sections
Follow us on
Available On